Edesa Biotech (EDSA) vs NanoViricides (NNVC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Edesa Biotech (EDSA) has outperformed NanoViricides (NNVC) over the past year, gaining 17.6% versus a loss of 10.2%. Over five years, NNVC leads with a -76.5% price change compared with -95.6% for EDSA. NanoViricides is the larger company by market cap ($29.1 million vs $27.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDSA | NNVC |
|---|---|---|
| Share price | $2.00 | $1.14 |
| Market cap | $27.02M | $29.13M |
| 1-day change | -8.05% | -2.56% |
| YTD return | +40.85% | +0.88% |
| 1-year return | +17.65% | -10.24% |
| 5-year return | -95.63% | -76.54% |
| EPS (TTM) | $-1.72 | $-0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-7.19M | $-8.22M |
| 52-week high | $20.32 | $1.93 |
| 52-week low | $0.72 | $0.85 |
| Distance from 52-week high | -90.16% | -40.93% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +716.50% | +426.32% |
| Average volume | 1.45M | 356.86K |
| Shares outstanding | 13.51M | 25.55M |
| Employees | 17 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDSA has outperformed NNVC by 27.9 percentage points over the past year.
About Edesa Biotech
EDSA stock →Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
About NanoViricides
NNVC stock →NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection; The latter, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
EDSA vs NNVC FAQ
Which is bigger, Edesa Biotech or NanoViricides?
NanoViricides (NNVC) is larger, with a market capitalization of $29.13M compared with $27.02M for Edesa Biotech (EDSA).
Which stock has performed better over the past year, EDSA or NNVC?
EDSA returned +17.65% over the past 12 months, compared with -10.24% for NNVC (price return, excluding dividends). Past performance does not predict future results.
Are Edesa Biotech and NanoViricides in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.